But its very interesting to learn about the kinds of breakthroughs that may be around the corner, she adds
Inoue, K., Hisatomi, A., Umeda, F
The exorbitant cost is the biggest reason why this trend is taking off
P = 0.017) compared to nonfatal myocardial infarction (HR 0.96
One is Virta Health, which advertises its nutrition-focused weight management program as "a proven approach for deprescribing GLP-1s when clinically appropriate." A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virta's program, concluding that their weight did not significantly increase after a year
The same study revealed that 70% of employers who do not currently cover GLP-1s for obesity would consider adding it if the prices were lower